Detalles de la búsqueda
1.
Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond "maculopapular rash".
Immunol Rev
; 318(1): 22-36, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37583051
2.
SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data.
Brief Bioinform
; 25(3)2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38701421
3.
Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
Br J Dermatol
; 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38366637
4.
Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma.
J Am Acad Dermatol
; 90(2): 288-298, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797836
5.
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
J Am Acad Dermatol
; 88(6): 1265-1270, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36944564
6.
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
J Am Acad Dermatol
; 88(5): 1024-1032, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36736626
7.
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
J Am Acad Dermatol
; 88(6): 1308-1316, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828138
8.
Seasonal Patterns in Tetracycline-Associated Hyperpigmentation Among Patients With Acne Vulgaris.
J Drugs Dermatol
; 22(11): e9-e11, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37943268
9.
Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study.
J Drugs Dermatol
; 22(8): 840-843, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37556518
10.
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
J Am Acad Dermatol
; 86(3): 563-572, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33819538
11.
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Oncologist
; 26(5): e898-e901, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33783099
12.
Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Oncologist
; 26(6): 514-522, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33655682
13.
Evolving phenotypes of non-hospitalized patients that indicate long COVID.
BMC Med
; 19(1): 249, 2021 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34565368
14.
Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey.
J Am Acad Dermatol
; 85(2): 396-403, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31415837
15.
De novo autoimmune connective tissue disease and mortality in patients treated with anti-PD-1 and anti-PD-L1 therapy: a population-level cohort study.
Br J Dermatol
; 2024 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38676955
16.
Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center.
J Am Acad Dermatol
; 90(3): 648-650, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37977293
17.
Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors: A multi-institutional cohort study.
J Am Acad Dermatol
; 90(5): 1080-1083, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38290617
18.
Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study.
J Am Acad Dermatol
; 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38341147
19.
Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional study.
J Am Acad Dermatol
; 90(1): 189-192, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37730018
20.
Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study.
J Am Acad Dermatol
; 90(2): 418-420, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37838257